Changes are happening - please bear with us while we update our site.

Changes are happening - please bear with us while we update our site. Click here to give us your advice and feedback.

Is Healius (ASX:HLS) The Best Healthcare Share On The ASX?

Is Healius Ltd (ASX:HLS) the best healthcare share on the ASX after issuing a business update?

Is Healius Ltd (ASX: HLS) the best healthcare share on the ASX after issuing a business update?

Healius, formerly known as Primary Health Care Limited (ASX: PRY), is a healthcare business that provides pathology, diagnostic imaging, medical centres and low-cost fertility services, such as IVF. It operates across thousands of sites Australia wide.

What Healius Announced

Healius said it’s going through an organisational restructure to improve efficiency and growth for the company.

Healius Managing Director and CEO Dr Malcolm Parmenter said: “This re-design is a continuation of the previously announced productivity program and is integral to delivering on our stated strategy.”

Management are seeking the ‘leanest and most agile’ structures possible. As part of the changes for the company, Chief Financial Officer Malcolm Ashcroft will be leaving Healius after the FY19 result has been completed.

CEO of the Pathology business Wes Lawrence will also be leaving the company who has been with Healius for 25 years. Succession plans for these two roles are well advanced and an announcement is expected shortly.

Healius’ Profit Expectations

Whilst Healius hasn’t yet prepared its full year report, it was able to provide some preliminary numbers.

The unaudited numbers showed all divisions improving in the second half compared to the first half. The company is expecting to deliver a result at the lower end of its guidance range of underlying net profit after tax (NPAT) of between $93 million to $98 million, which is in line with market expectations.

Is Healius The Best Healthcare Share?

There are a number of exciting healthcare shares that have a large technology element like Pro Medicus Limited (ASX: PME) and Volpara Health Technologies Ltd (ASX: VHT) which are priced highly.

But then there are other healthcare shares with lower margins and lower growth which are priced with lower price / earnings ratios like Healius and Ramsay Health Care Limited (ASX: RHC).

Healius is defensive and probably better priced than others in the healthcare sector. But, I’d rather go for one of the reliable shares in the free report below instead.

[ls_content_block id=”14945″ para=”paragraphs”]

[ls_content_block id=”18380″ para=”paragraphs”]

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

Skip to content